ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Nektar Ends Inhaled Insulin Programs

April 14, 2008 | APPEARED IN VOLUME 86, ISSUE 15

Nektar Therapeutics, a developer of drug delivery technologies, has stopped efforts to find a partner for its inhaled insulin program after Pfizer, its former partner, released negative clinical results last week. An ongoing review of clinical data for the Pfizer product Exubera showed an increase in lung cancer cases among former smokers using inhaled insulin compared with a control group. Pfizer pulled Exubera from the market in October 2007 after 18 months of limited patient interest and dismal sales. To conclude their product development relationship, Pfizer paid Nektar $135 million and agreed to transfer product rights if Nektar found another partner.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment